Corindus Vascular Robotics Release: Corpath System And The Benefits Of Robotic-Assisted PCI To Be Featured For The First Time In Japan

CorPath’s robotic precision and protection from occupational hazards highlighted for attending physicians at CVIT 2015

WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, announces that Augusto D. Pichard, M.D., interventional cardiologist at Washington Hospital Center and Professor of Medicine at the George Washington University Medical Center, will discuss how robotic-assisted percutaneous coronary interventions (PCI) are applied in a modern cath lab during his presentation entitled “Robotic Coronary Angioplasty” at the 24^th Annual Meeting of the Japanese Association of Cardiovascular Intervention and Therapeutics: CVIT 2015 in Fukuoka City, Japan, on July 30.

“Management’s Discussion and Analysis of Financial Condition and Results of Operations”

Japan is a large market for interventional cardiology, with 250,000 PCIs performed annually across 1,000 hospitals, and has historically shown interest in robotics and radiation protection. Corindus has been invited by Takafumi Ueno, M.D., Ph.D., President of CVIT 2015, to participate and present the CorPath System in the exhibit hall for hands-on demonstrations to attendees.

“While many devices have been introduced in Japan since the first coronary intervention was performed here more than 35 years ago, we had a limited number of innovations that offered both protection for physicians and potential to improve clinical outcomes,” said Dr. Ueno, Professor of Medicine, Cardiovascular Center, Kurume University Hospital. “The interventional cardiology community is open to new ideas and innovative technologies and we welcome the CorPath System to help us explore the advantages a robotic system can add to our practice.”

Corindus’ CorPath System is the first FDA-cleared medical device to bring robotically assisted precision to coronary angioplasty procedures in the U.S. The CorPath System is used in cath labs throughout the U.S. for complex PCIs. In addition to allowing cardiologists to advance stents and guidewires with millimeter-by-millimeter precision using digital controls, the system enables physicians to perform procedures while seated in a lead-lined interventional cockpit protected from radiation exposure.

“CorPath is already providing robotic precision during PCI procedures while protecting physicians from the serious occupational hazards in interventional cardiology here in the United States,” said David Handler, President and CEO of Corindus. “Japan is an important market for interventional cardiology and it is an honor to be invited to participate in this year’s CVIT conference.”

Physicians interested in viewing the CorPath System demonstration during CVIT 2015 need to register in advance. For additional information, visit http://www2.convention.co.jp/cvit2015/en/index.html. For more information about the CorPath System, visit www.corindus.com.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The Company’s FDA-cleared CorPath System is the first medical device that offers interventional cardiologists PCI procedure control from a radiation protective interventional cockpit. With the CorPath System, Corindus Vascular Robotics brings robotic precision to PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications through of improper stent placement with manual PCI procedures. Corindus stands behind its product with its unique $1,000 hospital credit “One Stent Program.” For additional information, visit www.corindus.com, and follow @CorindusInc.

Statements made in this release that are not statements of historical or current facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus Vascular Robotics to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus Vascular Robotics’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of Corindus Vascular Robotics. Examples of such statements include statements regarding the potential benefits of the CorPath System and robotic-assisted PCI for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: the rate of adoption of the CorPath System and the rate of use of CorPath Cassettes; risks associated with market acceptance, including pricing and reimbursement; Corindus Vascular Robotics’ ability to enforce its intellectual property rights; the need for additional funds to support operations; the ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend sales; and the effect of credit, financial and economic conditions on capital spending by potential customers. More information on potential factors that could affect Corindus Vascular Robotics’ financial results is included from time to time in the “Forward-Looking Statements,” “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Corindus Vascular Robotics’ periodic and current filings with the SEC, as well as those discussed under the “Risk Factors” and “Forward-Looking Statements” section of Corindus Vascular Robotics’ Quarterly Report on Form 10-K filed with the SEC on March 30, 2015 and available on its website at http://www.corindus.com/about-corindus/investor-relations. Forward-looking statements speak only as of the date they are made and Corindus Vascular Robotics undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, that occur after that date.

Help employers find you! Check out all the jobs and post your resume.